Absci Corporation (ABSI)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)
Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Absci Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 870 | $5,805.7 | $7,725.6 | $1,919.9 | 33.07% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 24,279 | $281,390 | $215,597.52 | -$65,792.48 | -23.38% |
| NA Nizar Araji National Bank Of Canada /FI/ | 1,025 | $3,326.91 | $9,102 | $5,775.09 | 173.59% |
| BG Bart Gancher Intech Investment Management LLC | 23,550 | $59,110.5 | $209,124 | $150,013.5 | 253.78% |
 John H. Burbank III Passport Capital LLC | 2.13M | $7.45M | $18.6M | $11.15M | 149.71% |
Absci Corporation (ABSI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Absci Corporation ever had a stock split?
Absci Corporation Profile
| Biotechnology Industry | Healthcare Sector | Sean McClain CEO | NASDAQ (NGS) Exchange | 00091E109 CUSIP |
| US Country | 140 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Absci Corporation is positioned at the forefront of the pharmaceutical industry as a pioneering data-first generative artificial intelligence (AI) drug creation company based in the United States. Founded in 2011 and headquartered in Vancouver, Washington, Absci sets itself apart by integrating AI with scalable wet laboratory technologies. This unique fusion is geared towards the expeditious creation of biologic drugs aimed at addressing patients' needs across various conditions. The company’s innovative approach aims to enhance the traditional biologic drug discovery process. By leveraging AI, it seeks to concurrently optimize several drug attributes critical to development and therapeutic efficacy. Absci has also established a collaborative effort with the Memorial Sloan Kettering Cancer Center, focusing on the discovery of novel therapeutics through the use of generative AI, underscoring its commitment to advancing medical research and treatment.
Products and Services
- Integrated Drug Creation Platform
This flagship offering by Absci harnesses the power of generative AI in conjunction with scalable wet lab technologies to revolutionize the biologic drug discovery process. The platform is meticulously designed to optimize multiple drug characteristics simultaneously, significantly improving the efficiency and efficacy of developing therapeutic biologics. This holistic approach not only accelerates the pipeline of drug discovery but also ensures that the drugs developed are of high therapeutic potential, catering to the nuanced needs of patients.
- Collaborative Research in Therapeutic Discovery
The partnership with Memorial Sloan Kettering Cancer Center showcases Absci's dedication to leveraging its generative AI and wet lab expertise in the quest for groundbreaking therapeutics. By working closely with a leading cancer research institution, Absci not only extends its scientific prowess into oncology but also enriches its drug discovery platform with valuable insights into cutting-edge cancer treatments. This collaboration represents a strategic effort to fuse AI’s predictive capabilities with clinical insights, aiming to uncover novel therapeutic pathways and options for patients.
Contact Information
